Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology.

Boga SB, Deng Y, Zhu L, Nan Y, Cooper AB, Shipps GW Jr, Doll R, Shih NY, Zhu H, Sun R, Wang T, Paliwal S, Tsui HC, Gao X, Yao X, Desai J, Wang J, Alhassan AB, Kelly J, Patel M, Muppalla K, Gudipati S, Zhang LK, Buevich A, Hesk D, Carr D, Dayananth P, Black S, Mei H, Cox K, Sherborne B, Hruza AW, Xiao L, Jin W, Long B, Liu G, Taylor SA, Kirschmeier P, Windsor WT, Bishop R, Samatar AA.

ACS Med Chem Lett. 2018 Jun 14;9(7):761-767. doi: 10.1021/acsmedchemlett.8b00220. eCollection 2018 Jul 12.

PMID:
30034615
2.

Discovery of 3(S)-thiomethyl pyrrolidine ERK inhibitors for oncology.

Boga SB, Alhassan AB, Cooper AB, Doll R, Shih NY, Shipps G, Deng Y, Zhu H, Nan Y, Sun R, Zhu L, Desai J, Patel M, Muppalla K, Gao X, Wang J, Yao X, Kelly J, Gudipati S, Paliwal S, Tsui HC, Wang T, Sherborne B, Xiao L, Hruza A, Buevich A, Zhang LK, Hesk D, Samatar AA, Carr D, Long B, Black S, Dayananth P, Windsor W, Kirschmeier P, Bishop R.

Bioorg Med Chem Lett. 2018 Jun 15;28(11):2029-2034. doi: 10.1016/j.bmcl.2018.04.063. Epub 2018 Apr 26.

PMID:
29748051
3.

Discovery of hydroxyaniline amides as selective Extracellular Regulated Kinase (Erk) inhibitors.

Zhu HY, Desai J, Deng Y, Cooper A, Wang J, Shipps J, Samatar A, Carr D, Windsor W.

Bioorg Med Chem Lett. 2015 Apr 1;25(7):1627-9. doi: 10.1016/j.bmcl.2015.01.049. Epub 2015 Feb 4.

PMID:
25716905
4.

Discovery of novel, dual mechanism ERK inhibitors by affinity selection screening of an inactive kinase.

Deng Y, Shipps GW Jr, Cooper A, English JM, Annis DA, Carr D, Nan Y, Wang T, Zhu HY, Chuang CC, Dayananth P, Hruza AW, Xiao L, Jin W, Kirschmeier P, Windsor WT, Samatar AA.

J Med Chem. 2014 Nov 13;57(21):8817-26. doi: 10.1021/jm500847m. Epub 2014 Oct 22.

PMID:
25313996
5.

Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor.

Deng Y, Shipps GW Jr, Zhao L, Siddiqui MA, Popovici-Muller J, Curran PJ, Duca JS, Hruza AW, Fischmann TO, Madison VS, Zhang R, McNemar CW, Mayhood TW, Syto R, Annis A, Kirschmeier P, Lees EM, Parry DA, Windsor WT.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):199-203. doi: 10.1016/j.bmcl.2013.11.041. Epub 2013 Nov 23.

PMID:
24332088
6.

In vitro kinetic profiling of hepatitis C virus NS3 protease inhibitors by progress curve analysis.

Zhang R, Windsor WT.

Methods Mol Biol. 2013;1030:59-79. doi: 10.1007/978-1-62703-484-5_6.

PMID:
23821260
7.

Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

Morris EJ, Jha S, Restaino CR, Dayananth P, Zhu H, Cooper A, Carr D, Deng Y, Jin W, Black S, Long B, Liu J, Dinunzio E, Windsor W, Zhang R, Zhao S, Angagaw MH, Pinheiro EM, Desai J, Xiao L, Shipps G, Hruza A, Wang J, Kelly J, Paliwal S, Gao X, Babu BS, Zhu L, Daublain P, Zhang L, Lutterbach BA, Pelletier MR, Philippar U, Siliphaivanh P, Witter D, Kirschmeier P, Bishop WR, Hicklin D, Gilliland DG, Jayaraman L, Zawel L, Fawell S, Samatar AA.

Cancer Discov. 2013 Jul;3(7):742-50. doi: 10.1158/2159-8290.CD-13-0070. Epub 2013 Apr 24.

8.

Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor.

Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, Seghezzi W, Paruch K, Dwyer MP, Doll R, Nomeir A, Windsor W, Fischmann T, Wang Y, Oft M, Chen T, Kirschmeier P, Lees EM.

Mol Cancer Ther. 2010 Aug;9(8):2344-53. doi: 10.1158/1535-7163.MCT-10-0324. Epub 2010 Jul 27.

9.

3-phosphoinositide-dependent protein kinase-1 regulates proliferation and survival of cancer cells with an activated mitogen-activated protein kinase pathway.

Lu Z, Cox-Hipkin MA, Windsor WT, Boyapati A.

Mol Cancer Res. 2010 Mar;8(3):421-32. doi: 10.1158/1541-7786.MCR-09-0179. Epub 2010 Mar 2.

10.

Structure-guided discovery of cyclin-dependent kinase inhibitors.

Fischmann TO, Hruza A, Duca JS, Ramanathan L, Mayhood T, Windsor WT, Le HV, Guzi TJ, Dwyer MP, Paruch K, Doll RJ, Lees E, Parry D, Seghezzi W, Madison V.

Biopolymers. 2008 May;89(5):372-9.

PMID:
17937404
11.

Method for quantitative protein-ligand affinity measurements in compound mixtures.

Annis DA, Shipps GW Jr, Deng Y, Popovici-Müller J, Siddiqui MA, Curran PJ, Gowen M, Windsor WT.

Anal Chem. 2007 Jun 15;79(12):4538-42. Epub 2007 May 15.

PMID:
17500537
13.

Expression and purification of phosphorylated and non-phosphorylated human MEK1.

Smith CK, Carr D, Mayhood TW, Jin W, Gray K, Windsor WT.

Protein Expr Purif. 2007 Apr;52(2):446-56. Epub 2006 Nov 9.

PMID:
17175166
14.

A structurally guided method for the decomposition of expression in music performance.

Windsor WL, Desain P, Penel A, Borkent M.

J Acoust Soc Am. 2006 Feb;119(2):1182-93.

PMID:
16521779
15.
16.

Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.

Nallan L, Bauer KD, Bendale P, Rivas K, Yokoyama K, Hornéy CP, Pendyala PR, Floyd D, Lombardo LJ, Williams DK, Hamilton A, Sebti S, Windsor WT, Weber PC, Buckner FS, Chakrabarti D, Gelb MH, Van Voorhis WC.

J Med Chem. 2005 Jun 2;48(11):3704-13.

PMID:
15916422
17.

Fluorescence polarization assay and inhibitor design for MDM2/p53 interaction.

Zhang R, Mayhood T, Lipari P, Wang Y, Durkin J, Syto R, Gesell J, McNemar C, Windsor W.

Anal Biochem. 2004 Aug 1;331(1):138-46.

PMID:
15246006
18.

Development of a fluorescence polarization bead-based coupled assay to target different activity/conformation states of a protein kinase.

Lu Z, Yin Z, James L, Syto R, Stafford JM, Koseoglu S, Mayhood T, Myers J, Windsor W, Kirschmeier P, Samatar AA, Malcolm B, Turek-Etienne TC, Kumar CC.

J Biomol Screen. 2004 Jun;9(4):309-21.

PMID:
15191648
19.

Double-stranded DNA-induced localized unfolding of HCV NS3 helicase subdomain 2.

Liu D, Windsor WT, Wyss DF.

Protein Sci. 2003 Dec;12(12):2757-67.

20.

Improving tolerance of Candida antarctica lipase B towards irreversible thermal inactivation through directed evolution.

Zhang N, Suen WC, Windsor W, Xiao L, Madison V, Zaks A.

Protein Eng. 2003 Aug;16(8):599-605.

PMID:
12968077
21.

Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.

Taveras AG, Aki C, Chao J, Doll RJ, Lalwani T, Girijavallabhan V, Strickland CL, Windsor WT, Weber P, Hollinger F, Snow M, Patton R, Kirschmeier P, James L, Liu M, Nomeir A.

J Med Chem. 2002 Aug 29;45(18):3854-64.

PMID:
12190309
22.

Azapeptides as inhibitors of the hepatitis C virus NS3 serine protease.

Zhang R, Durkin JP, Windsor WT.

Bioorg Med Chem Lett. 2002 Apr 8;12(7):1005-8.

PMID:
11909704
23.

Farnesyl protein transferase: identification of K164 alpha and Y300 beta as catalytic residues by mutagenesis and kinetic studies.

Wu Z, Demma M, Strickland CL, Radisky ES, Poulter CD, Le HV, Windsor WT.

Biochemistry. 1999 Aug 31;38(35):11239-49.

PMID:
10471273
24.

Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships.

Strickland CL, Weber PC, Windsor WT, Wu Z, Le HV, Albanese MM, Alvarez CS, Cesarz D, del Rosario J, Deskus J, Mallams AK, Njoroge FG, Piwinski JJ, Remiszewski S, Rossman RR, Taveras AG, Vibulbhan B, Doll RJ, Girijavallabhan VM, Ganguly AK.

J Med Chem. 1999 Jun 17;42(12):2125-35.

PMID:
10377218
25.

A continuous spectrophotometric assay for the hepatitis C virus serine protease.

Zhang R, Beyer BM, Durkin J, Ingram R, Njoroge FG, Windsor WT, Malcolm BA.

Anal Biochem. 1999 Jun 1;270(2):268-75.

PMID:
10334844
26.

High-level expression, purification, kinetic characterization and crystallization of protein farnesyltransferase beta-subunit C-terminal mutants.

Wu Z, Demma M, Strickland CL, Syto R, Le HV, Windsor WT, Weber PC.

Protein Eng. 1999 Apr;12(4):341-8.

PMID:
10325405
27.

Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue.

Strickland CL, Windsor WT, Syto R, Wang L, Bond R, Wu Z, Schwartz J, Le HV, Beese LS, Weber PC.

Biochemistry. 1998 Nov 24;37(47):16601-11.

PMID:
9843427
28.

Structural and biological stability of the human interleukin 10 homodimer.

Syto R, Murgolo NJ, Braswell EH, Mui P, Huang E, Windsor WT.

Biochemistry. 1998 Dec 1;37(48):16943-51.

PMID:
9836587
29.

Thermodynamic and structural analysis of phosphotyrosine polypeptide binding to Grb2-SH2.

McNemar C, Snow ME, Windsor WT, Prongay A, Mui P, Zhang R, Durkin J, Le HV, Weber PC.

Biochemistry. 1997 Aug 19;36(33):10006-14.

PMID:
9254595
30.

Probing the substrate specificity of hepatitis C virus NS3 serine protease by using synthetic peptides.

Zhang R, Durkin J, Windsor WT, McNemar C, Ramanathan L, Le HV.

J Virol. 1997 Aug;71(8):6208-13.

31.

Characterization of Ha-ras, N-ras, Ki-Ras4A, and Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I.

Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR.

J Biol Chem. 1997 Apr 11;272(15):10232-9.

32.

Purification and crystallization of a complex between human interferon gamma receptor (extracellular domain) and human interferon gamma.

Windsor WT, Walter LJ, Syto R, Fossetta J, Cook WJ, Nagabhushan TL, Walter MR.

Proteins. 1996 Sep;26(1):108-14.

PMID:
8880934
33.

Novel tricyclic inhibitors of farnesyl protein transferase. Biochemical characterization and inhibition of Ras modification in transfected Cos cells.

Bishop WR, Bond R, Petrin J, Wang L, Patton R, Doll R, Njoroge G, Catino J, Schwartz J, Windsor W, et al.

J Biol Chem. 1995 Dec 22;270(51):30611-8.

34.

Crystal structure of a complex between interferon-gamma and its soluble high-affinity receptor.

Walter MR, Windsor WT, Nagabhushan TL, Lundell DJ, Lunn CA, Zauodny PJ, Narula SK.

Nature. 1995 Jul 20;376(6537):230-5.

PMID:
7617032
35.

Crystallization and preliminary X-ray investigation of recombinant human interleukin 10.

Cook WJ, Windsor WT, Murgolo NJ, Tindall SH, Nagabhushan TL, Walter MR.

Proteins. 1995 Jun;22(2):187-90.

PMID:
7567966
36.

A homology model of human interferon alpha-2.

Murgolo NJ, Windsor WT, Hruza A, Reichert P, Tsarbopoulos A, Baldwin S, Huang E, Pramanik B, Ealick S, Trotta PP.

Proteins. 1993 Sep;17(1):62-74.

PMID:
8234245
37.

Disulfide bond assignments and secondary structure analysis of human and murine interleukin 10.

Windsor WT, Syto R, Tsarbopoulos A, Zhang R, Durkin J, Baldwin S, Paliwal S, Mui PW, Pramanik B, Trotta PP, et al.

Biochemistry. 1993 Aug 31;32(34):8807-15.

PMID:
8364028
38.

Kinetics of oxygen binding and subunit assembly for the hemoglobin alpha subunit.

Windsor WT, Philo JS, Potschka M, Schuster TM.

Biophys Chem. 1992 May;43(1):61-71.

PMID:
1633259
39.

A point mutation of human interferon gamma abolishes receptor recognition.

Lunn CA, Fossetta J, Dalgarno D, Murgolo N, Windsor W, Zavodny PJ, Narula SK, Lundell D.

Protein Eng. 1992 Apr;5(3):253-7.

PMID:
1409546
40.

Selective proteolytic cleavage of recombinant human interleukin 4. Evidence for a critical role of the C-terminus.

Le HV, Seelig GF, Syto R, Ramanathan L, Windsor WT, Borkowski D, Trotta PP.

Biochemistry. 1991 Oct 8;30(40):9576-82.

PMID:
1911743
41.
43.
44.

Fibrinous peritonitis: a complication of practolol therapy.

Windsor WO, Durrein F, Dyer NH.

Br Med J. 1975 Apr 12;2(5962):68. No abstract available.

Supplemental Content

Loading ...
Support Center